Published in J Mol Neurosci on January 01, 2004
Designing prevention programmes to reduce incidence of dementia: prospective cohort study of modifiable risk factors. BMJ (2010) 3.37
Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease. Ann Neurol (2010) 2.16
Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging (2009) 2.14
Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum Mol Genet (2010) 1.90
Genetic determinants of human health span and life span: progress and new opportunities. PLoS Genet (2007) 1.70
Neurogenesis and Alzheimer's disease: at the crossroads. Exp Neurol (2009) 1.54
Feelings of Hopelessness in Midlife and Cognitive Health in Later Life: A Prospective Population-Based Cohort Study. PLoS One (2015) 1.39
Genome-wide DNA methylation differences between late-onset Alzheimer's disease and cognitively normal controls in human frontal cortex. J Alzheimers Dis (2012) 1.27
The genetic architecture of Alzheimer's disease: beyond APP, PSENs and APOE. Neurobiol Aging (2010) 1.25
Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic mice. BMC Neurosci (2008) 1.20
Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders. Curr Alzheimer Res (2012) 1.19
iTRAQ analysis of complex proteome alterations in 3xTgAD Alzheimer's mice: understanding the interface between physiology and disease. PLoS One (2008) 1.16
Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities. J Cell Mol Med (2008) 1.16
Using genetics to enable studies on the prevention of Alzheimer's disease. Clin Pharmacol Ther (2012) 1.14
Apolipoprotein E genotype is associated with temporal and hippocampal atrophy rates in healthy elderly adults: a tensor-based morphometry study. J Alzheimers Dis (2011) 1.09
Peripheral delivery of a CNS targeted, metalo-protease reduces aβ toxicity in a mouse model of Alzheimer's disease. PLoS One (2011) 1.07
APOE genotype and neuroimaging markers of Alzheimer's disease: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry (2014) 1.04
Activation of estrogen receptor alpha increases and estrogen receptor beta decreases apolipoprotein E expression in hippocampus in vitro and in vivo. Proc Natl Acad Sci U S A (2006) 1.03
Complex and multidimensional lipid raft alterations in a murine model of Alzheimer's disease. Int J Alzheimers Dis (2010) 1.00
Antioxidant therapy in Alzheimer's disease: theory and practice. Mini Rev Med Chem (2008) 1.00
Genetic connections between neurological disorders and cholesterol metabolism. J Lipid Res (2010) 0.98
Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease. J Neurosci (2009) 0.98
Role of synucleins in Alzheimer's disease. Neurotox Res (2009) 0.98
Evidence for impaired amyloid β clearance in Alzheimer's disease. Alzheimers Res Ther (2013) 0.97
CDK5 activator protein p25 preferentially binds and activates GSK3β. Proc Natl Acad Sci U S A (2014) 0.89
The apolipoprotein E (APOE) gene appears functionally monomorphic in chimpanzees (Pan troglodytes). PLoS One (2012) 0.87
Age and apoE associations with complex pathologic features in Alzheimer's disease. J Neurol Sci (2008) 0.87
Human apolipoprotein E redistributes fibrillar amyloid deposition in Tg-SwDI mice. J Neurosci (2008) 0.87
Four-year outcome of mild cognitive impairment: the contribution of executive dysfunction. Neuropsychology (2012) 0.87
The roles of lipid and glucose metabolism in modulation of β-amyloid, tau, and neurodegeneration in the pathogenesis of Alzheimer disease. Front Aging Neurosci (2015) 0.87
A neuroprotective brain-penetrating endopeptidase fusion protein ameliorates Alzheimer disease pathology and restores neurogenesis. J Biol Chem (2014) 0.87
Alzheimer's disease and environmental exposure to lead: the epidemiologic evidence and potential role of epigenetics. Curr Alzheimer Res (2012) 0.86
Low plasma leptin in cognitively impaired ADNI subjects: gender differences and diagnostic and therapeutic potential. Curr Alzheimer Res (2014) 0.86
Impact of gene patents and licensing practices on access to genetic testing for Alzheimer disease. Genet Med (2010) 0.86
Repositioning leptin as a therapy for Alzheimer's disease. Therapy (2011) 0.85
ApoE4-dependent Abeta-mediated neurodegeneration is associated with inflammatory activation in the hippocampus but not the septum. J Neural Transm (Vienna) (2009) 0.83
Brain aging and dementia during the transition from late adulthood to old age: design and methodology of the "Invece.Ab" population-based study. BMC Geriatr (2013) 0.83
Dietary deficiency increases presenilin expression, gamma-secretase activity, and Abeta levels: potentiation by ApoE genotype and alleviation by S-adenosyl methionine. J Neurochem (2009) 0.83
Imaging the Alzheimer brain. J Alzheimers Dis (2011) 0.83
F-spondin gene transfer improves memory performance and reduces amyloid-β levels in mice. Neuroscience (2012) 0.81
Possible modification of Alzheimer's disease by statins in midlife: interactions with genetic and non-genetic risk factors. Front Aging Neurosci (2014) 0.80
Additional mechanisms conferring genetic susceptibility to Alzheimer's disease. Front Cell Neurosci (2015) 0.79
Effects of apoE deficiency and occlusal disharmony on amyloid-beta production and spatial memory in rats. PLoS One (2013) 0.78
Does APOE explain the linkage of Alzheimer's disease to chromosome 19q13? Am J Med Genet B Neuropsychiatr Genet (2008) 0.77
Genome-wide haplotype association study identify TNFRSF1A, CASP7, LRP1B, CDH1 and TG genes associated with Alzheimer's disease in Caribbean Hispanic individuals. Oncotarget (2015) 0.76
Drivers: A Biologically Contextualized, Cross-Inferential View of the Epidemiology of Neurodegenerative Disorders. J Alzheimers Dis (2016) 0.76
Multiple kernel learning with random effects for predicting longitudinal outcomes and data integration. Biometrics (2015) 0.75
Alzheimer's disease: new therapies and the role of biomarkers. Biotechnol Healthc (2011) 0.75
Is ApoE ɛ 4 a good biomarker for amyloid pathology in late onset Alzheimer's disease? Transl Neurodegener (2016) 0.75
Meta-analysis of association between the genetic polymorphisms on chromosome 11q and Alzheimer's disease susceptibility. Int J Clin Exp Med (2015) 0.75
Human Central Nervous System (CNS) ApoE Isoforms are Increased by Age, Differentially Altered by Amyloidosis, and Relative Amounts Reversed in the CNS Compared to Plasma. J Biol Chem (2016) 0.75
Mutation-based structural modification and dynamics study of amyloid beta peptide (1-42): An in-silico-based analysis to cognize the mechanism of aggregation. Genom Data (2016) 0.75
Neuropsychiatric symptoms and Apolipoprotein E: Associations with eventual Alzheimer's disease development. Arch Gerontol Geriatr (2016) 0.75
A critical appraisal of dementia with special reference to Smritibuddhihrass. Ayu (2013) 0.75
Genetic Polymorphisms Influence Cognition in Patients Undergoing Carotid Interventions. Int J Angiol (2016) 0.75
What is aging? What is its role in Alzheimer's disease? What can we do about it? J Alzheimers Dis (2005) 0.79